Scientists Discover New Life-Saving Benefit of Ozempic and Semaglutide
A nationwide study in Sweden indicates that GLP1 agonists, such as Ozempic, could lower the risk of cirrhosis and liver cancer in individuals with type 2 diabetes and chronic liver disease, suggesting a new, effective treatment option for preventing severe liver diseases.A nationwide study conducted by the Karolinska Institutet in Sweden, published in the journal Gut, indicates that the use of Ozempic and similar GLP1 agonists is linked to a lower likelihood of cirrhosis and liver cancer in individuals with type 2…